Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: DRUG: Akt Inhibitor MK2206|OTHER: Laboratory Biomarker Analysis|DRUG: Lapatinib Ditosylate|OTHER: Pharmacogenomic Study|OTHER: Pharmacological Study
Sponsor: National Cancer Institute (NCI)